RBPJL

RBPJL is a sequence-specific DNA-binding transcription factor that serves as the Notch-independent counterpart of RBP-J (CSL/RBPJ), recognizing a nearly identical DNA motif yet unable to interact with Notch intracellular domains (PMID:9111338). In mature pancreatic acinar cells, RBPJL replaces RBP-J as the third subunit of the trimeric PTF1 complex (forming PTF1-L with PTF1a/p48 via conserved tryptophan motifs), driving terminal acinar differentiation by directly activating digestive enzyme genes, secretory apparatus components, and mitochondrial metabolism genes (PMID:16354684, PMID:20398665). RBPJL also represses Arid5a transcription to suppress IL-6/STAT3 inflammatory signaling in acinar cells and, outside the pancreas, cooperates with FAM102A and RUNX2 to promote osteoblast differentiation through nuclear translocation and SP7/Osterix activation (PMID:35725649, PMID:39747056). Cell-type-specific expression is governed by distinct promoters that direct RBPJL transcription in pancreas, lung, and specific neuronal populations including hippocampal pyramidal cells and cortical layer VI neurons (PMID:10502683, PMID:11549321).

1. 1997 High

   The discovery that RBP-L binds the same DNA motif as RBP-J yet cannot interact with any Notch intracellular domain established RBPJL as a Notch-independent paralogue, raising the question of what transcriptional programs it controls independently of Notch signaling.

   Evidence DNA-binding assays, co-immunoprecipitation, and GST pulldown in mammalian cells

   PMID:9111338

   Open questions at the time

   • No endogenous target genes or tissue-specific functions identified
   • Physiological protein partners beyond Notch remained unknown
   • Whether RBPJL participates in a larger transcription complex was untested
2. 1999 Medium

   Knockin reporter experiments revealed that RBPJL expression is controlled by two distinct promoters — an upstream neuronal promoter active in cortical and hippocampal neurons and a downstream promoter active in lung — establishing cell-type specificity and raising the question of distinct functions across tissues.

   Evidence Targeted nlacZ knockin replacement, β-galactosidase histochemistry, and quantitative RT-PCR in mouse brain and lung

   PMID:10502683

   Open questions at the time

   • Pancreatic expression and its regulatory elements were not characterized in this study
   • Functional consequence of RBPJL loss in neurons was not assessed
   • Neuronal target genes remain unidentified
3. 2001 Medium

   Genomic characterization showed the Rbpjl locus overlaps antisense with Matn4 and produces a truncated transcript variant lacking 121 N-terminal amino acids, clarifying locus architecture but leaving variant-specific function unresolved.

   Evidence Genomic cloning, RT-PCR, in situ hybridization, and transcription start site mapping in mouse tissues

   PMID:11549321

   Open questions at the time

   • Functional significance of the truncated N-terminal variant is unknown
   • Whether antisense overlap with Matn4 has regulatory consequences was not tested
4. 2006 High

   Identification of RBPJL as the third subunit of the PTF1-L trimeric complex — recruited by PTF1a/p48 through two tryptophan motifs — established the molecular basis for Notch-independent transcriptional control in pancreatic acinar cells.

   Evidence Co-immunoprecipitation, mutagenesis of tryptophan motifs, ChIP, and transcriptional reporter assays

   PMID:16354684

   Open questions at the time

   • Genome-wide target genes of PTF1-L versus PTF1-J were not distinguished
   • In vivo consequence of RBPJL loss on acinar cell differentiation was untested
5. 2010 High

   Conditional Rbpjl knockout demonstrated that the PTF1-J-to-PTF1-L switch is required for terminal acinar maturation, with ~90% of downregulated genes being direct PTF1-L targets encoding digestive enzymes and secretory machinery — answering the in vivo functional requirement.

   Evidence Conditional Rbpjl knockout mouse, mRNA profiling, and ChIP for direct target identification

   PMID:20398665

   Open questions at the time

   • Whether residual PTF1-J compensation masks additional PTF1-L functions was not resolved
   • Structural basis for PTF1-L versus PTF1-J target selectivity is unknown
6. 2018 Medium

   A population-specific p.Thr280Met variant was shown to reduce RBPJL protein stability and impair transactivation of exocrine gene promoters, linking natural human genetic variation in RBPJL to quantitative differences in acinar gene expression.

   Evidence Luciferase reporter assays, overexpression and siRNA knockdown in mouse acinar cells, protein versus mRNA level comparison of variant alleles

   PMID:29302047

   Open questions at the time

   • No clinical phenotype was definitively associated with this variant
   • Structural mechanism of reduced protein stability for Met280 is unknown
   • Effect on PTF1-L complex assembly was not directly tested
7. 2022 Medium

   Discovery that RBPJL directly binds and represses the Arid5a promoter to suppress IL-6/STAT3 signaling revealed a previously unknown anti-inflammatory role in pancreatic acinar cells, extending RBPJL function beyond digestive enzyme activation.

   Evidence ChIP, EMSA, dual-luciferase reporter, overexpression/knockdown in acinar cells, cerulein-induced acute pancreatitis mouse model

   PMID:35725649

   Open questions at the time

   • Whether Arid5a repression occurs through the PTF1-L complex or RBPJL acting independently is unclear
   • Genome-wide scope of RBPJL-mediated transcriptional repression has not been mapped
   • Single-lab finding awaiting independent replication
8. 2025 Medium

   The finding that FAM102A physically interacts with RBPJL and promotes its nuclear translocation together with RUNX2 to activate SP7/Osterix and drive osteoblast differentiation established RBPJL as a regulator of bone formation outside the pancreas.

   Evidence Co-immunoprecipitation, nuclear translocation assays, conditional Fam102a knockout and Rbpjl functional mutation mice, bone histomorphometry

   PMID:39747056

   Open questions at the time

   • Whether RBPJL forms a complex analogous to PTF1 in osteoblasts is unknown
   • Direct DNA targets of RBPJL in bone cells have not been identified by ChIP
   • Single-lab finding; independent confirmation needed

• The neuronal function of RBPJL — expressed in hippocampal pyramidal neurons, dentate gyrus, and cortical layer VI — remains entirely uncharacterized at the mechanistic level, with no target genes, binding partners, or loss-of-function phenotypes identified in the nervous system.
• No neuronal target genes or transcriptional programs have been defined
• Whether RBPJL participates in a PTF1-like complex in neurons is unknown
• Behavioral or neurological consequences of neuronal RBPJL loss are untested